We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

128 hedge funds and large institutions have $766M invested in Acceleron Pharma in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 65 increasing their positions, 28 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 28

21% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 14

2% more funds holding

Funds holding: 125128 (+3)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

37% less capital invested

Capital invested by funds: $1.21B → $766M (-$447M)

69% less call options, than puts

Call options by funds: $2.08M | Put options by funds: $6.71M

Holders
128
Holders Change
+3
Holders Change %
+2.4%
% of All Funds
3.41%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
17
Increased
65
Reduced
28
Closed
14
Calls
$2.08M
Puts
$6.71M
Net Calls
-$4.63M
Net Calls Change
+$4.79M
Name Holding Trade Value Shares
Change
Change in
Stake
CAM
26
Cormorant Asset Management
Massachusetts
$5.28M
BG
27
BlackRock Group
United Kingdom
$5.04M +$2.16M +74,285 +64%
FCMI
28
Foresite Capital Management II
California
$4.59M +$1.07M +36,631 +27%
CS
29
Credit Suisse
Switzerland
$3.72M +$1.41M +48,518 +53%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$3.48M +$715K +24,578 +23%
VSI
31
Verde Servicos Internacionais
Brazil
$3.34M +$1.32M +45,550 +56%
Lord, Abbett & Co
32
Lord, Abbett & Co
New Jersey
$3.31M -$750K -25,776 -17%
PI
33
Putnam Investments
Massachusetts
$3.3M
BIM
34
BlackRock Investment Management
Delaware
$3.11M +$383K +13,183 +13%
CS
35
Candriam SCA
Luxembourg
$3.02M -$145K -5,000 -4%
Charles Schwab
36
Charles Schwab
California
$2.81M +$439K +15,094 +17%
Principal Financial Group
37
Principal Financial Group
Iowa
$2.63M
FCMI
38
Foresite Capital Management III
California
$2.49M +$1.29M +44,356 +89%
TC
39
TFS Capital
Pennsylvania
$2.43M -$548K -18,858 -17%
Prudential Financial
40
Prudential Financial
New Jersey
$2.38M +$625K +21,500 +31%
TCIM
41
TIAA CREF Investment Management
New York
$2.36M +$589K +20,263 +29%
Morgan Stanley
42
Morgan Stanley
New York
$2.27M +$2.12M +72,915 +553%
PAMU
43
Pictet Asset Management (UK)
United Kingdom
$2.18M
IHM
44
Iguana Healthcare Management
New York
$1.98M -$2.18M -75,000 -50%
CCP
45
Clough Capital Partners
Massachusetts
$1.79M -$4.07M -139,900 -67%
TD Asset Management
46
TD Asset Management
Ontario, Canada
$1.61M -$58.2K -2,000 -3%
Alyeska Investment Group
47
Alyeska Investment Group
Illinois
$1.58M +$1.74M +60,000 New
PP
48
PDT Partners
New York
$1.54M +$965K +33,195 +131%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$1.37M +$339K +11,654 +29%
USAA
50
United Services Automobile Association
Texas
$1.34M +$20.4K +700 +1%

XLRN Hedge Fund Activity: Q1 2016 in Review

128 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2016, worth a combined $766M — down 37% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new XLRN positions and 14 closed out — a net gain of 3 holders — while 65 added to existing stakes and 28 trimmed.

The largest buyer was Eagle Asset Management, opening a new position worth an estimated $22.6M. The largest seller was Millennium Management, cutting an estimated $19.7M.

  • 128 institutional investors held Acceleron Pharma (XLRN) as of Q1 2016, up from 125 in Q4 2015.
  • Funds reported $766M of Acceleron Pharma stock for Q1 2016, down 37% quarter-over-quarter.
  • 17 funds opened new Acceleron Pharma positions in Q1 2016 and 14 closed out, a net change of +3 holders.
  • The largest Acceleron Pharma buyer in Q1 2016 was Eagle Asset Management, an estimated $22.6M added.
  • The largest Acceleron Pharma seller in Q1 2016 was Millennium Management, an estimated $19.7M sold.

Based on aggregated 13F filings for Q1 2016.